Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Optimization Trial in Chronic Myeloid Leukemia (CML) - Randomized Controlled Comparison of Imatinib vs. Imatinib/Interferon-alpha vs. Imatinib/Low-Dose AraC vs. Interferon-alpha Standard Therapy and Determination of the Role of Allografting in Newly Diagnosed Chronic Phase

NCT00055874 is registered in ClinicalTrials.gov with Heidelberg University as lead sponsor.

NCT NCT00055874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00055874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Optimization Trial in Chronic Myeloid Leukemia (CML) - Randomized Controlled Comparison of Imatinib vs. Imatinib/Interferon-alpha vs. Imatinib/Low-Dose AraC vs. Interferon-alpha Standard Therapy and Determination of the Role of Allografting in Newly Diagnosed Chronic Phase
Lead sponsor
Heidelberg University
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2002
Completion date
March 31, 2017
Enrollment
1,551 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia